Tozaro
Tozaro uses molecular modelling and machine learning to design specific polymers that bind to gene therapy vectors, making production more stable, selective and accessible compared to traditional protein-based technologies.
Europe's most interesting startup stories. Every week.
No spam. Unsubscribe anytime.
Podcast Episode
🎙️ Deep Dive
Daily News – 16 February 2026
Listen to the episodeAbout Tozaro
Tozaro (formerly MIP Discovery) is a British biotech founded in 2015 in Bedford, Bedfordshire. The company uses molecular modelling and ML to develop smart polymers capable of specifically binding to gene therapy vectors (such as adeno-associated viruses), reducing production costs that currently represent one of the main barriers to gene therapy adoption. The Smart Polymer platform uses over 500 chemical groups to create specific binding compounds, compared to ~20 amino acids used by traditional protein-based technologies. In February 2026 it raised €6.9M led by Mercia Ventures, bringing total raised to €27.2M.
Market & Clients
Key Customers
Gene therapy manufacturers, biopharmaceutical research centres and viral vector developers.
Geographic Presence
Funding & Investors
Funding Rounds
- 2026 - Growth round: €6M
Key Investors
Similar Startups
Ternary Therapeutics
Biotech company using synthetic biology to develop therapies for serious diseases with innovative treatment approaches.
Read AnalysisSTORM Therapeutics
Biotech company developing targeted therapies using proprietary cell-targeting technology.
Read Analysis